Trial reportThe American journal on addictions2018
Abstinence and reduced frequency of use are associated with improvements in quality of life among treatment-seekers with cannabis use disorder.
Trial report in The American journal on addictions, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01020019 (A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence), which is not on this map. Cited by 21 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized, Double-Blind, Placebo-Controlled Study of Lofexidine and Dronabinol for the Treatment of Marijuana Dependence
Who cites it
21 citing papers in PubMed, 3 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Pharmacotherapies for cannabis use disorder.The Cochrane database of systematic reviews · 2025Pooled it
- Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications.BMC medicine · 2022Pooled it
- Systematic review of outcome domains and measures used in psychosocial and pharmacological treatment trials for cannabis use disorder.Drug and alcohol dependence · 2019Pooled it
- A preliminary randomized controlled trial of repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex in treatment seeking participants with cannabis use disorder.Drug and alcohol dependence · 2024Trial
- Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors · 2022Trial
- Impact of a computerized intervention for high distress intolerance on cannabis use outcomes: A randomized controlled trial.Journal of substance abuse treatment · 2021Trial
- Beyond abstinence: Redefining success in cannabis use disorder treatment.Addiction (Abingdon, England) · 2026Article
- Quality of life measures in treatment for active substance misuse: a scoping review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- ADHD and Alcohol Use Disorder: Optimizing Screening and Treatment in Co-occurring Conditions.CNS drugs · 2025Review
- Association of Cannabis Use Reduction With Improved Functional Outcomes: An Exploratory Aggregated Analysis From Seven Cannabis Use Disorder Treatment Trials to Extract Data-Driven Cannabis Reduction Metrics.The American journal of psychiatry · 2024Article
- Reduced drug use as an alternative valid outcome in individuals with stimulant use disorders: Findings from 13 multisite randomized clinical trials.Addiction (Abingdon, England) · 2024Article
- Perceived Risks and Therapeutic Benefits of Cannabis Among College Students Amidst the COVID-19 Pandemic.Cannabis (Albuquerque, N.M.) · 2023Article
- Abstinence versus moderation recovery pathways following resolution of a substance use problem: Prevalence, predictors, and relationship to psychosocial well-being in a U.S. national sample.Alcoholism, clinical and experimental research · 2022Article
- A "Good" Smoke? The Off-Label Use of Cannabidiol to Reduce Cannabis Use.Frontiers in psychiatry · 2022Article
- Patterns of reduced use and abstinence in multi-site randomized controlled trials of pharmacotherapies for cocaine and methamphetamine use disorders.Drug and alcohol dependence · 2021Article
- Non-abstinent treatment outcomes for cannabis use disorder.Drug and alcohol dependence · 2021Article
- Cannabis use and cannabis use disorder.Nature reviews. Disease primers · 2021Review
- The state of clinical outcome assessments for cannabis use disorder clinical trials: A review and research agenda.Drug and alcohol dependence · 2020Review
- Measuring Within-Individual Cannabis Reduction in Clinical Trials: A Review of the Methodological Challenges.Current addiction reports · 2019Article
- Relationships between marijuana use, severity of marijuana-related problems, and health-related quality of life.Psychiatry research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
BACKGROUND AND
objectiveMany patients with cannabis use disorder (CUD) do not achieve or do not have abstinence as a goal of treatment, rather they reduce their use. Assessing outcome measures as they relate to functioning and reductions in cannabis use is an important area of study. Quality of life (QoL) shows promise as one such measure. Past studies have demonstrated gender differences in QoL and CUD. We aim to assess (1) the relationship between cannabis use and QoL and (2) gender effects in an outpatient medication treatment study for CUD.
methodsData from an 11-weeks, double-blind, placebo-controlled trial of lofexidine and dronabinol for CUD (n = 62) was analyzed. Pearson's correlations between baseline QoL as measured with the Quality of Life, Enjoyment, and Satisfaction Questionnaire-Short Form (QLES-Q-SF) and cannabis use assessed with modified timeline follow-back (TLFB) were examined. Multiple linear regression models of cannabis use on end of study QLES-Q-SF were analyzed, while adjusting for baseline QLES-Q-SF, study arm, and gender. Moderation effects with gender were also tested.
resultsNo significant association between baseline cannabis use and QoL was found. End of study abstinence (F DISCUSSION AND
conclusionsAbstinence and lower frequency of use are associated with higher QoL, regardless of gender. SCIENTIFIC SIGNIFICANCE: This is the first time QoL has been demonstrated to change over the course of CUD medication treatment. QoL is an important outcome in CUD treatment.
trial registrationNCT01020019. (Am J Addict 2018;27:101-107).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.